Sector News

Sanofi and Lonza enter partnership to build biologics facility

February 28, 2017
Life sciences

The large-scale facility, to be built in Visp, Switzerland, will be established through a joint venture with an initial investment of around CHF 290 million (€270 million) shared equally between Sanofi and Lonza

The strategic partnership leverages Lonza’s expertise in large-scale mammalian cell culture facilities alongside Sanofi’s strength in developing and launching biologics based treatments to address patient needs. Lonza will construct the facility and will support the joint venture in its operation of the facility.

The initial phase of the facility will commence construction in 2017, pending necessary regulatory approvals, and is expected to be fully operational by 2020. Lonza has previously built and licensed three similar facilities in the US and Singapore.

Marc Funk is COO Pharma & Biotech at Lonza. He said: “We intend to address long-term market needs by establishing a state-of-the-art strategic biologics manufacturing platform.

“Approximately 60% of our pipeline is made up of biologics, including monoclonal antibodies, dedicated to key disease areas such as cardiovascular, immunology and inflammation, neurology and oncology,” said Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi.

“Lonza is a highly experienced partner in this field and the capabilities this joint venture will create are critical to meeting our patients’ needs for these important therapies.”

The partnership provides both Sanofi and Lonza with substantial flexibility:

  • Each party will share the available capacity in line with their equity shareholding in the joint venture
  • Sanofi will have additional access to bio-manufacturing capacity
  • Lonza will be free to market their share of capacity and will also market unused Sanofi capacity

The strategic partnership enables Sanofi to react quickly to fluctuations in demand in a short timeframe, reinforcing their capability to launch high-quality, next generation biologic medicines and ensure consistent access for patients.

It also provides Lonza with the capacity to respond to growing manufacturing demands for large-scale mammalian cell culture based therapeutic proteins. By adding flexibility in this way, it is hoped this model will optimise biologics production capacity across the whole industry.

Source: Manufacturing Chemist

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”